Avidicure, an Amsterdam, The Netherlands-based biotechnology company pioneering an entirely new multifunctional antibody modality with broad applicability in oncology, raised $50m in seed financing.
The round was led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures.
Led by Arthur Lahr, Chief Executive Officer, Avidicure is developing dual agonistic, multifunctional and avidity engineered antibodies, “AVC-Boosters”, that can safely deliver targeted and potent cancer monotherapy. AVC-Boosters unlock orchestrated immunological responses, harnessing the full power of both the innate and adaptive immune system. The AVC-Booster design surpasses the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers, and antibody-drug conjugates (ADCs).
Avidicure’s fully owned proprietary platform leverages decades of antibody engineering and in silico protein design capabilities, and immunology expertise. Through the AVC-Booster plug-and-play functionality, multiple products can be developed. Avidicure’s lead product, AVC-S-101, is a TROP2-targeting booster that is being developed for non-small cell lung cancer and multiple other indications.
The founding management team consists of Arthur Lahr (CEO), Dirk De Naeyer (COO), Robert Friesen (CSO), and Govert Schouten (CBO),
The Supervisory Board includes industry veterans Frank Verwiel (Intellia, Aptalis, Bavarian Nordic, Merck & Co.), Martijn Kleijwegt (EQT-LS), Hunter Smith (Rhythm), and Helen Collins (Five Prime, Enliven, Gilead, Amgen).
FinSMEs
24/04/2025